About this trial
(a) Objectives
1. To assess the full lung function, exercise capacity, quality of life in patients with COVID-19 over 2 years. 2. To assess the longevity of the serology response to SARS-CoV2. 3. To investigate the association of the neutralization titer in plasma from different vaccinated cohorts to its protection of infection using in vivo model 4. To investigate the SARS-CoV-2 specific cellular and humoral immunities as well as their determinant factors from community subjects who have received different types of COVID-19 vaccines. 5. To assess the third booster dose for subjects who have poor antibody response despite having received two doses of CoronaVac (Sinovac)
Eligibility criteria
Qualifiers
None
Disqualifiers
None
Trial design
Treatments tested in this trial
- third dose vaccination with CoronaVac vaccine
- third dose vaccination with BionTech vaccine
- Vaccination with Coronavac vaccine
- Vaccination with BionTech Vaccine
Treatment groups
Sponsors and collaborators
Chinese University of Hong Kong
Lead sponsor
The University of Hong Kong
Collaborator
Health and Medical Research Fund
Collaborator